Development of a Chlamydia sp. vaccine strain
US8021672B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Feb 20, 2007 |
| Grant date | Sep 20, 2011 |
| Priority date | — |
| Expiry date | Mar 23, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12R2001/01
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention involves the discovery that Chlamydia sp. strains can be cured of their plasmids by treatment with novobiocin, and that plasmid-deficient strains are defective in infecting cells under standard conditions, but can infect cells if centrifuged onto the host cells. But it is found that plasmid-deficient strains with wild-type infection efficiency under standard conditions can be isolated as mutants from parent plasmid-deficient strains with low infectivity by selecting for infection under standard conditions. Both the less infective and the highly infective plasmid-deficient strains were able to infect mice with little or no pathological symptoms, and both reduced the pathology in mice later challenged with the parental wild-type disease-causing Chlamydia strain. Thus, plasmid-deficient Chlamydia are effective vaccine strains. The invention provides a process for isolating a plasmid-deficient strain of Chlamydia sp., a process for developing a plasmid-deficient strain of Chlamydia sp. for use as a vaccine, a process for developing a highly infective plasmid-deficient strain of Chlamydia sp., isolated Chlamydia sp. strains, a method of expressing a recombinant nucleic aci…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.